Congratulations to Amgen on the approval of Tarlatamab in extensive-stage small cell lung cancer (ES-SCLC)! This marks the second T cell engager to receive FDA approval in solid tumors, and a significant leap forward in SCLC treatment. This milestone also energizes our commitment to advancing T cell engager programs in solid tumors. It reminds us of our mission to transform the lives of patients everywhere by mastering the discovery, development and delivery of off-the-shelf precision T cell engagers. #Oncology #CancerResearch #TCellEngagers #SCLC #Amgen #PharmaInnovation #PatientCare
Today, the U.S. FDA approved Amgen’s delta-like ligand 3-targeting Bispecific T-cell Engager (BiTE®) immunotherapy in adults with extensive-stage small cell lung cancer (ES-SCLC). Amgen is proud to deliver the first targeted immunotherapy to this patient population. 🔗 Press release: https://amgen.ly/3X35AWL
